In a release issued under the same headline on September 13, 2019 by European High Growth Opportunities Securitization Fund, please note that in the third paragraph of the release, the correct number of Common Shares is 8,936,484, not 67,752,095 Common Shares as previously stated. The corrected release follows:
TORONTO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- European High Growth Opportunities Securitization Fund (the “Fund”) announced today the conversion of $300,000 of its aggregate $700,000 of Debentures (as defined below) of Alternate Health Corp. (“Alternate Health” or the "Company") (CSE:AHG) (OTCQB:AHGIF) between July 23, 2019 and September 3, 2019 (collectively, the “Conversions”) and the sale of an aggregate 1,645,111 Shares (as defined below) between July 12, 2019 and September 6, 2019.
Pursuant to the terms of a financing arrangement (the “Financing”), the Company issued to the Fund a convertible debenture (the “Debenture”) in the principal aggregate amount of $700,000 and share purchase warrants (the “Warrants”) exercisable to acquire up to an aggregate of 3,348,484 common shares of the Company (the “Shares”). The Debenture and Warrants otherwise have the terms described in the Company’s press releases dated July 5, 2019 and July 17, 2019. Further terms of the Financing are set out in the Subscription Agreements as filed on SEDAR and available under the Company’s profile at www.sedar.com.
Immediately following the closing of the Financing, the Acquiror owned, controlled or directed (directly or indirectly): (i) an aggregate principal amount of $700,000 Debentures; and (ii) 3,348,484 Warrants. Based on the foregoing, the Acquiror, directly or indirectly, beneficially owned or exercised control or direction over 8,936,484 Common Shares, representing approximately 13.19% of the issued and outstanding Common Shares on a non-diluted basis (assuming the conversion of the aggregate principal amount of $700,000 Debentures and the exercise of the 3,348,484 Warrants) and 12.14% of the issued and outstanding Common Shares on a diluted basis.
After giving effect to the Conversions and the sale of Shares, the Acquiror owns, controls or directs (directly or indirectly): (i) an aggregate principal amount of $400,000 Debentures; and (ii) 3,348,484 Warrants, representing 10.58% of the issued and outstanding Common Shares on a non-diluted basis (assuming the conversion of the aggregate principal amount of $700,000 Debentures and the exercise of an aggregate of 3,348,484 Warrants) and 9.89% of the issued and outstanding Common Shares on a diluted basis.
Debentures and Warrants were acquired by the Fund for investment purposes. Depending on market and other conditions, the Fund may, directly or indirectly, acquire ownership or control over additional securities of the Company, through open market or through private acquisitions or sell securities of the Company either on the open market or through private dispositions in the future depending on market conditions and/or other relevant factors.
This press release is issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which also requires a report to be filed with regulatory authorities in which the Company is a reporting issuer containing information with respect to the foregoing matters (the “Early Warning Report”). A copy of the Early Warning Report will appear at www.sedar.com under the Company’s profile.
The address of the Fund is:
European High Growth Opportunities Securitization Fund
25 Hanover Square, 2nd and 6th Floor
London W1S 1JF
United Kingdom
About Alternate Health
Alternate Health is an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Through Alternate Health's subsidiary, Blaine Labs, the Company has 23 years of experience in FDA-registered and cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health's innovative software systems provide the platform for the company's diverse operations, including CBD product distribution, hemp-derived extract manufacturing, blockchain tax collection systems and electronic medical records (EMR) platforms. Alternate Health's corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders. For more information about Alternate Health Corp., visit www.alternatehealth.com.
About European High Growth Opportunities Securitization Fund
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Fund cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.
Contact:
Pierre Vannineuse
+44 (0) 203 855 0088
